BSc · MBBS · PGDip (Oncology) · MRCP · FRCR · MD
Clinical Lead for Brachytherapy at Mount Vernon Cancer Centre.
Urological and gynaecological oncology, complex interstitial brachytherapy,
systemic therapies — radical and palliative.
Dr Mohammed Abdul-Latif is a Consultant Clinical Oncologist and Clinical Lead for Brachytherapy at Mount Vernon Cancer Centre, with specialist training in urological and gynaecological malignancies.
He trained at Imperial College School of Medicine, graduating in the top decile of his cohort with distinctions across multiple subjects. He subsequently completed a Postgraduate Diploma in Oncology at the Institute of Cancer Research, his Membership of the Royal College of Physicians (MRCP), and his Fellowship of the Royal College of Radiologists (FRCR).
His Doctorate of Medicine (MD), completed at the University of Manchester under Professor Peter Hoskin, focused on functional MRI in cervical cancer — work he continues to present internationally, including as a first-author proffered paper at ESTRO.
His clinical practice covers the full spectrum of oncological management across urological and gynaecological cancers, delivered with both radical and palliative intent. He has a particular interest in complex interstitial and intracavitary brachytherapy, and is one of a small number of clinicians in the UK trained to deliver brachytherapy across such a wide range of indications — including salvage and re-irradiation cases.
He also manages patients on systemic therapies including chemotherapy, immunotherapy, and targeted therapies, and has a specific interest in the management of pelvic radiation disease.
He speaks English and Arabic. He is recognised by all major private health insurers, including as a Bupa Platinum, Fee Assured consultant. He also holds an Education Fellowship at the Institute of Cancer Research and is Module Lead for Oncology for Brunel Medical School students at Mount Vernon Cancer Centre.
Dr Abdul-Latif's practice combines a broad oncological remit with specific technical expertise in brachytherapy — from routine intracavitary treatments through to complex interstitial implants, salvage re-irradiation and organ-preserving approaches.
Clinical Lead at Mount Vernon Cancer Centre. Trained in gynaecological, urological, rectal, oesophageal, breast, skin and soft tissue brachytherapy — including salvage and re-irradiation, and organ-preservation approaches.
Management of prostate, bladder, cervical, endometrial, vaginal and vulval cancers, including chemoradiotherapy and concurrent systemic treatments, delivered with both radical and palliative intent.
IMRT, VMAT, and stereotactic ablative radiotherapy (SABR/SBRT). SpaceOAR hydrogel spacer insertion for prostate cancer. Image-guided radiotherapy (IGRT) and MRI-guided adaptive planning.
Chemotherapy, immunotherapy and targeted therapies across gynaecological and urological malignancies — in both curative and palliative settings, including concurrent chemoradiotherapy.
Management of pelvic radiation disease in both the acute and chronic phase — a clinically important area for patients who have undergone pelvic radiotherapy, and a specific research and clinical interest.
Regular first-author presenter at ESTRO; published in Clinical Oncology, Brachytherapy, BMJ Open, BMJ Oncology, and Cancer Treatment Reviews. Education fellow at the Institute of Cancer Research.
Salvage and re-irradiation brachytherapy — including breast-conserving approaches to avoid mastectomy, and rectal-preserving approaches to avoid a stoma — is an area requiring highly specialised training and experience, and represents an alternative for patients where standard options have been exhausted.
A full range of radiotherapy, brachytherapy and systemic treatment services, across urological and gynaecological malignancies and beyond. All modalities are offered with both radical and palliative intent as appropriate.
Intracavitary and interstitial brachytherapy for cervical, endometrial, vaginal and vulval cancers. MRI-guided adaptive planning. Includes salvage and re-irradiation brachytherapy for recurrent gynaecological malignancy.
High-dose-rate (HDR) prostate brachytherapy as monotherapy or boost, and permanent seed implant (LDR). SpaceOAR hydrogel spacer insertion to protect the rectum. Includes focal salvage HDR brachytherapy for locally relapsed prostate cancer.
Contact radiotherapy and interstitial brachytherapy for rectal and oesophageal cancers. Includes organ-preserving brachytherapy for rectal cancer and re-irradiation of recurrent disease to avoid surgical resection.
Interstitial brachytherapy for breast cancer where mastectomy would otherwise be required, and for skin and soft tissue indications. Salvage brachytherapy for second ipsilateral breast events is a specific area of clinical expertise.
External beam radiotherapy including Intensity-Modulated Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT), and Stereotactic Ablative Body Radiotherapy (SABR/SBRT) for prostate, spinal metastases, and other indications.
Systemic anti-cancer therapies across gynaecological and urological cancers, including concurrent chemoradiotherapy and standalone systemic treatment. Manages patients on a range of agents from chemotherapy to immunotherapy and targeted therapies.
Dr Abdul-Latif publishes regularly and has presented as first author at multiple ESTRO congresses and other international meetings. His research covers brachytherapy, functional imaging in cervical cancer, systemic therapies, and radiation-related toxicity.
View full publication list on Google ScholarBMJ Oncology — Abdul-Latif M, Conibear J, Thiruthaneeswaran N, Tsang YM
Brachytherapy, Volume 23, Issue 2 — Abdul-Latif M et al. PMID 38383205
Clinical Oncology — Armstrong S, Makris A, Belessiotis-Richards K, Abdul-Latif M et al.
BMJ Open — Abdul-Latif M, Choudhury A, Tharmalingam H et al.
Clinical Oncology — Abdul-Latif M et al. PMID 37246040
Clinical Oncology — Sherriff J, Abdul-Latif M, Tsang YM. PMID 36710152
Cancer Treatment Reviews — Abdul-Latif M et al. PMID 32505807
Clinical Oncology, Volume 31, Issue 2 — Abdul-Latif M et al.
Research Focus
Brachytherapy outcomes across gynaecological, urological, GI and breast cancers. Multiple first-author proffered papers at ESTRO, including salvage brachytherapy and functional MRI.Doctoral Research
Functional MRI of the cervix during chemoradiotherapy — MD(Res) awarded by the University of Manchester under Professor Peter Hoskin, 2025.Pelvic Radiation Disease
Management of radiation-related complications in the acute and chronic phase — an under-recognised area of oncological care that Dr Abdul-Latif is actively researching and improving.
Fees may vary. Please contact the secretary to confirm before booking.
Video and telephone consultations also available.
Self-pay patients welcome. All major insurers accepted.
Recognised Insurers
Dr Abdul-Latif holds Bupa Platinum status and is Fee Assured — Bupa patients do not incur excess charges on his consultations.
For appointments, referrals, or general enquiries, please contact Dr Abdul-Latif's medical secretary. Self-pay and all major insurers are accepted.
Medical Secretary
Amy Bignell
